NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity PA-17-157 from the NIH Guide for Grants and Contracts. Genetic and genomic studies have identified genes and gene variants that may impact the fundamental biological mechanisms underpinning substance use disorders (SUDs). Discovery of these genes/variants, while extremely valuable, is only the first step in understanding the molecular processes that influence SUDs. This Funding Opportunity Announcement (FOA) encourages basic functional genetic and genomic research in two areas: 1. functional validation to determine which candidate genes/variants/epigenetic/non-coding RNA features have an authentic role in SUDs, and 2. detailed elucidation of the molecular pathways and processes modulated by candidate genes/variants, particularly for those genes with an unanticipated role in SUDs.
Funding Opportunity PA-17-155 from the NIH Guide for Grants and Contracts. Genetic and genomic studies have identified genes and gene variants that may impact the fundamental biological mechanisms underpinning substance use disorders (SUDs). Discovery of these genes/variants, while extremely valuable, is only the first step in understanding the molecular processes that influence SUDs. This Funding Opportunity Announcement (FOA) encourages basic functional genetic and genomic research in two areas: 1. functional validation to determine which candidate genes/variants/epigenetic/non-coding RNA features have an authentic role in SUDs, and 2. detailed elucidation of the molecular pathways and processes modulated by candidate genes/variants, particularly for those genes with an unanticipated role in SUDs.
Funding Opportunity PAR-17-156 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to accelerate research evaluating electronic cigarettes (e-cigarettes, electronic nicotine delivery systems, ENDS) as a potential means of reducing the risks associated with combustible tobacco use. This goal will be achieved by funding clinical studies that use the newly-developed NIDA Standard Research E-cigarette (SREC) to examine potential risks and benefits associated with e-cigarette use in current tobacco smokers. Ultimately, this FOA aims to evaluate whether e-cigarettes can reduce the risks associated with combustible tobacco use and to establish the NIDA SREC as a standard to which other e-cigarettes can be compared. Studies submitted to this FOA should examine the effects of the SREC on multiple behavioral and health biomarkers in current tobacco smokers and may include examination of whether e-cigarettes can reduce the negative health impacts of conventional tobacco use, and / or examine their effects on craving and dependence. Funding will be contingent upon the FDA Center for Tobacco Products (CTP) determination that the studies fall under their regulatory jurisdiction. Furthermore, funding will require that CTP accepts the use of the NIDA SREC as an Investigational Tobacco Product (ITP) in the proposed study, or determines that an ITP is not required. Studies funded by this FOA are expected to rapidly increase understanding of whether e-cigarettes reduce the risks associated with tobacco use. Additionally, these studies may provide significant data to inform e-cigarette public health policy decision-making.
Funding Opportunity PAR-17-158 from the NIH Guide for Grants and Contracts. This FOA seeks applications which propose secondary analyses of existing clinical research datasets to investigate constructs identified in the NIMH's Research Domain Criteria (RDoC) initiative and to test novel hypotheses using the RDoC framework.
Funding Opportunity RFA-FD-17-004 from the NIH Guide for Grants and Contracts. This program expansion FOA provides a mechanism for organizations receiving only competition A funding under PAR-16-137 to apply for competition B funding. Only those states/territories currently receiving funding for competition A under PAR-16-137 are eligible to apply.
Notice NOT-AG-17-004 from the NIH Guide for Grants and Contracts
Notice NOT-NS-17-016 from the NIH Guide for Grants and Contracts
Notice NOT-NS-17-015 from the NIH Guide for Grants and Contracts
Notice NOT-NS-17-013 from the NIH Guide for Grants and Contracts
Notice NOT-OD-17-041 from the NIH Guide for Grants and Contracts
Notice NOT-HL-17-486 from the NIH Guide for Grants and Contracts
Notice NOT-CA-17-023 from the NIH Guide for Grants and Contracts
Notice NOT-AI-17-012 from the NIH Guide for Grants and Contracts
Notice NOT-CA-17-026 from the NIH Guide for Grants and Contracts
Notice NOT-LM-17-004 from the NIH Guide for Grants and Contracts
Notice NOT-AT-17-004 from the NIH Guide for Grants and Contracts
Notice NOT-NS-17-014 from the NIH Guide for Grants and Contracts
Notice NOT-NS-17-012 from the NIH Guide for Grants and Contracts
Notice NOT-NS-17-011 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-17-153 from the NIH Guide for Grants and Contracts. The "epitranscriptome" refers to chemical modifications of RNA molecules. RNA modifications in the brain have been reported to regulate the fate and function of both coding and noncoding RNAs and are emerging as a critical element of cellular function. The purpose of this initiative is to stimulate research into the functions of modified RNAs in the brain and/or the associated modification proteins that act on RNA (readers, writers, and erasers) and play a role in basic neurobiological and behavioral processes implicated in mental and substance use disorders.